Bod Australia is looking to cash in on expected demand for cannabis-based treatments through plans to import an oil used to help children with epilepsy.
Bod chief executive Jo Patterson said the company had access to the world’s only consistent, reproducible, manufactured cannabis extract through Linnea.
The Sydney-based company expects to receive approval to import the extract in the coming months and it would then initially target sales at 25 approved prescribers of medicinal cannabis.
Read the full article on theaustralian.com.au